Poxel SA (POXEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Poxel SA (POXEL) has a cash flow conversion efficiency ratio of -0.124x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€7.59 Million ≈ $8.87 Million USD) by net assets (€-61.40 Million ≈ $-71.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Poxel SA stock valuation for the company's overall valuation and market capitalisation.
Poxel SA - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Poxel SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Poxel SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Poxel SA ranked by their cash flow conversion efficiency. Explore POXEL cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TIMES CHINA HLDGS HD -10
F:T2H
|
N/A |
|
INCOME ASSET MNG.GRP.LTD.
F:C1R
|
N/A |
|
PT Dafam Property Indonesia Tbk
JK:DFAM
|
1.537x |
|
Green Circle Decarbonize Technology Limited
NYSE MKT:GCDT
|
N/A |
|
Great Divide Mining Ltd
AU:GDM
|
-0.092x |
|
Livium Ltd
AU:LIT
|
-0.405x |
|
Vessel Co. Ltd
KQ:177350
|
-0.055x |
|
Rigsave S.P.A.
XETRA:H68
|
N/A |
Annual Cash Flow Conversion Efficiency for Poxel SA (2011–2024)
The table below shows the annual cash flow conversion efficiency of Poxel SA from 2011 to 2024. View latest Poxel SA stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-58.94 Million ≈ $-68.90 Million |
€-17.61 Million ≈ $-20.58 Million |
0.299x | +4.88% |
| 2023-12-31 | €-49.08 Million ≈ $-57.38 Million |
€-13.98 Million ≈ $-16.34 Million |
0.285x | -76.18% |
| 2022-12-31 | €-18.24 Million ≈ $-21.33 Million |
€-21.81 Million ≈ $-25.50 Million |
1.196x | +158.09% |
| 2021-12-31 | €8.21 Million ≈ $9.59 Million |
€-16.89 Million ≈ $-19.75 Million |
-2.059x | -114.90% |
| 2020-12-31 | €26.88 Million ≈ $31.42 Million |
€-25.75 Million ≈ $-30.10 Million |
-0.958x | -45.94% |
| 2019-12-31 | €39.14 Million ≈ $45.76 Million |
€-25.69 Million ≈ $-30.04 Million |
-0.656x | -671.83% |
| 2018-12-31 | €55.78 Million ≈ $65.22 Million |
€-4.74 Million ≈ $-5.55 Million |
-0.085x | -120.23% |
| 2017-12-31 | €19.33 Million ≈ $22.60 Million |
€8.13 Million ≈ $9.50 Million |
0.420x | +187.86% |
| 2016-12-31 | €39.39 Million ≈ $46.05 Million |
€-18.85 Million ≈ $-22.04 Million |
-0.479x | -80.88% |
| 2015-12-31 | €38.03 Million ≈ $44.46 Million |
€-10.06 Million ≈ $-11.76 Million |
-0.265x | -111.07% |
| 2014-12-31 | €-2.55 Million ≈ $-2.98 Million |
€-6.09 Million ≈ $-7.12 Million |
2.390x | +614.70% |
| 2013-12-31 | €-20.01 Million ≈ $-23.39 Million |
€-6.69 Million ≈ $-7.82 Million |
0.334x | +101.87% |
| 2012-12-31 | €315.03K ≈ $368.30K |
€-5.64 Million ≈ $-6.60 Million |
-17.912x | -1489.45% |
| 2011-12-31 | €7.35 Million ≈ $8.59 Million |
€-8.28 Million ≈ $-9.68 Million |
-1.127x | -- |
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more